Online inquiry

IVTScrip™ mRNA-Anti-ANGPT2&VEGFA, RG7716(Cap 0, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ14357MR)

This product GTTS-WQ14357MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets ANGPT2&VEGFA gene. The antibody can be applied in Diabetic macular edema, Age-related macular degeneration (AMD) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species Homo sapiens; Humanized
RefSeq NM_001118887.2; NM_001025366.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 285; 7422
UniProt ID O15123; P15692
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ANGPT2&VEGFA, RG7716(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ14357MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ13214MR IVTScrip™ mRNA-Anti-TNFRSF9, PF-05082566(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA PF-05082566
GTTS-WQ7013MR IVTScrip™ mRNA-Anti-CSF3R, F-627(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA F-627
GTTS-WQ9809MR IVTScrip™ mRNA-Anti-BTLA, JS004(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA JS004
GTTS-WQ14159MR IVTScrip™ mRNA-Anti-IL6R, aIL6R88(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA aIL6R88
GTTS-WQ15013MR IVTScrip™ mRNA-Anti-CSF1R, SNDX-6352(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA SNDX-6352
GTTS-WQ9769MR IVTScrip™ mRNA-Anti-PDCD1, JS001(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA JS001
GTTS-WQ5938MR IVTScrip™ mRNA-Anti-CD274, CK-301(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA CK-301
GTTS-WQ3402MR IVTScrip™ mRNA-Anti-ALB, aALB03(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA aALB03
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW